Study to Evaluate BIIB059 in CLE With or Without SLE (LILAC)
First filed June 2016, verified November 2018
This multicenter, Phase II, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study intends to evaluate the efficacy of BIIB059 in reducing skin disease activity in participants with systemic lupus erythematosus (SLE) (Part A), and in participants with active cutaneous lupus erythematosus (CLE) with or without systemic manifestations (Part B), and to investigate the dose response relationship in participants with active SLE and skin manifestations (Part A only).
Study sponsor: Biogen
To Learn More Contact
ClinicalTrials.gov identifier: NCT02847598